• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ra Medical Systems Inc.

    2/14/24 3:57:22 PM ET
    $RMED
    Medical/Dental Instruments
    Health Care
    Get the next $RMED alert in real time by email
    SC 13G 1 armistice-vtak123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Catheter Precision, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per shar

    (Title of Class of Securities)

     

    74933X302

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  74933X302
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    752,874
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    752,874
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    752,874
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  74933X302
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    752,874
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    752,874
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    752,874
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 74933X302
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Catheter Precision, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1670 Highway 160 West, Suite 205

    Fort Mill, South Carolina 29708

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    74933X302

     

    CUSIP No.  74933X302
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 74933X302
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2023:

    Armistice Capital, LLC - 752,874

    Steven Boyd - 752,874  

    (b) Percent of Class as of December 31, 2023:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 752,874

    Steven Boyd - 752,874 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 752,874

    Steven Boyd - 752,874

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 7,536,284 Shares outstanding as of December 19, 2023, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on December 21, 2023.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 74933X302
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 74933X302
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $RMED alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RMED

    DatePrice TargetRatingAnalyst
    10/21/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reminder: Ra Medical Systems Announces Name and Ticker Symbol Changes

      Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unv

      8/17/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Allowance of New Closure Device Patent

      First patent out of six applications on file for LockeT productFORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China.David Jenkins, interim CEO of Ra Medical Systems, commented, "We are pleased to see the first of what should be several patents to come about with the LockeT closure device. It is a clever design and invention,

      8/14/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Milestone Achievement for Electrophysiology Division

      Catheter Precision's VIVO System Has Been Utilized in over 1,000 ProceduresFORT MILL, SC / ACCESSWIRE / August 7, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today that VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures. VIVO, which stands for View Into Ventricular Onset, enables physicians to learn more about patient specific anatomy and better help them plan the ablation procedure. As a result, VIVO aids in reducing overall procedure time benefitting physicians, hospitals and patients."I made a conscious decision to support a pre-commercial roll out with my own capital. I've invested well over $25mm at an ave

      8/7/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    SEC Filings

    See more
    • Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/25/24 4:15:50 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/11/24 4:15:46 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Leadership Update

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/4/24 4:20:59 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Ra Medical Systems with a new price target

      HC Wainwright & Co. initiated coverage of Ra Medical Systems with a rating of Buy and set a new price target of $12.00

      10/21/21 6:17:16 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems downgraded by Maxim Group

      Maxim Group downgraded Ra Medical Systems from Buy to Hold

      3/17/21 8:31:51 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Ra Medical Systems Announces First Quarter Results

      FORT MILL, SC / ACCESSWIRE / June 2, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced financial and company highlights for the first quarter ended March 31,2023. Among the quarter highlights are the following:RMED concluded the acquisition with the private, company Catheter Precision, Inc. ("Catheter"), in January 2023. Catheter is in the MedTech space of cardiac electrophysiology.Catheter onboarded five direct salespersons and several field clinical persons to assist in the broad US launch of its VIVO product, a product utilized to non-invasively determine the source, or earliest activation, of a ventricular arrhythmia.Catheter introduced to the market its new LockeT closure devi

      6/2/23 6:35:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Announces Resignation of CEO

      Board Committee Seeking ReplacementFORT MILL, SC / ACCESSWIRE / April 18, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today the resignation of its CEO, Will McGuire, for personal reasons. The resignation will be effective April 28, 2023. In conjunction with his resignation as CEO, Mr. McGuire is also resigning from the RMED board of directors. The Company thanks Mr. McGuire for his service and contributions and wishes him the best in future endeavors.The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, will serve as Interim

      4/18/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Change in Chief Financial Officer Position Previous Acting CFO Position Replaced with Permanent Appointment

      FORT MILL, SC / ACCESSWIRE / March 30, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer."Steven joins the executive team at a pivotal time in Ra Medical's growth", stated Ra Medical's Executive Chairman of the Board David Jenkins. "His background with publicly traded companies, budget and cost control ensures we will maintain the highest standards as a public company. In addition, he is a seasoned executive who has led M&A transactions as well as numerous equity and debt financing transactions for strategic growth. His ex

      3/30/23 7:30:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Financials

    Live finance-specific insights

    See more
    • Ra Medical Systems Announces Date of Special Shareholder Meeting

      FORT MILL, SC / ACCESSWIRE / February 10, 2023 / Ra Medical Systems (NYSE:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting. Shareholders of record as of February 3, 2023 are entitled to vote at the meeting.Among other items, shareholders are requested to vote in favor of a previously announced $8 million private financing, and to vote in favor of the conversion of RMED preferred stock into common stock, the majority of which will not be converted until mid-2024, at the earliest. The preferred stock was issued in connection with the acquisition of Catheter Precision, Inc., earlier this year.About Ra Medical SystemsRa Medical, and its wholly owned

      2/10/23 9:20:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022

      Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

      5/9/22 6:50:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results

      Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months and full year ended December 31, 2021 and provides a business update. Recent Operational Highlights Filed 510(k) application with the FDA for our next-generation DABRA catheter that incorporates a braided overjacket designed to improve robustness and includes data supporting a six-month shelf life Enrolled 13 subjects in the company's atherectomy pivotal clinical study since mid-November 2021, for a total of 98 subjects enrolled, and received approv

      3/23/22 4:05:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Catheter Precision, Inc. (0001716621) (Subject)

      2/14/24 3:57:22 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)

      SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

      1/16/24 8:15:49 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Ra Medical Systems, Inc. (0001716621) (Subject)

      3/31/23 4:15:34 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care